Merck & Co., Inc. (MRK)
Merck to Buy Verona Pharma in $10 Billion Deal
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports
Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma, the Financial Times reported on Wednesday.
Merck & Co.: A Pharma Titan At A Discount
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its current market price, MRK is as much as 23% undervalued. Underlying fundamentals are still strong, with great margins, heavy R&D investing, and a plan to aggressively expand by CapEx spending totaling $20 billion from 2024 to 2028.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Dividend Yield Theory Says Merck Is A Buy
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expiration and political headwinds, Merck's robust pipeline and adaptability offer a credible path to future growth. DYT analysis projects a 42%-83% total return over four years, with Merck meeting or exceeding most fundamental quality metrics.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
